Barclays: BioMarin Is A Buy, Sees $150/Share By: Benzinga via Benzinga June 05, 2015 at 07:26 AM EDT In a report published Friday, Barclays analyst Geoff Meacham initiated coverage of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with an ... Read More >> Related Stocks: Biomarin Pharmaceuticals